Skip to main navigation
In order to offer and provide a customized and personal service through our products and websites, we may use cookies to store and help track information about you. ×
Logo

PIONEERING IMMUNOTHERAPY

Investor FAQs

Show all

Where is Aduro located?
Aduro’s corporate offices are located at:
740 Heinz Avenue
Berkeley, CA 94710
When was Aduro founded?
Aduro was incorporated in California under the name Oncologic, Inc. in 2000. In 2008, the company merged with Triton BioSystems, Inc. and subsequently changed its name to Aduro Biotech, Inc. In June 2011, the company reincorporated as a Delaware Corporation.
What is Aduro’s CUSIP number?
Aduro’s CUSIP number is 00739L101.
On what stock exchange and under what symbol are Aduro’s shares traded?
Aduro is listed under the NASDAQ Global Select Market under the ticker symbol ADRO.
How can I buy and sell shares of Aduro’s stock?
Aduro does not offer a direct purchase plan for investors. You may purchase Aduro’s stock through a licensed securities broker.
Who is Aduro’s transfer agent?
Aduro’s transfer agent is Computershare Trust Company, N.A. The transfer agent and registrar’s address is
250 Royall Street,
Canton, Massachusetts 02021.
Who do I contact regarding lost stock certificates, address changes, and changes of ownership or name in which shares are held?
Please contact our transfer agent:
Computershare Trust Company, N.A.
250 Royall Street
Canton, Massachusetts 02021.
Does Aduro issue dividends on its common stock?
Aduro does not pay cash dividends on its common stock and does not anticipate doing so in the foreseeable future.
Who are Aduro’s independent auditors?
Our independent auditors are:
Deloitte & Touche LLP
555 Mission Street
San Francisco, CA 94105
415.783.4000.
Who is Aduro’s outside legal counsel?
Cooley LLP
3175 Hanover Street
Palo Alto, CA 94304
650.843.5000
When is Aduro’s fiscal year end?
Our fiscal year end is December 31.
Do you have another question that has not been answered?
Please contact IR through the form on the Contact page.

Investor Toolkit

  • Print Page
  • RSS Feeds
  • Email Alerts

Investor Relations

  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • FAQs
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Headquarters
    • Community Affairs
  • Pipeline
    • Clinical Trials
    • Access to Our Investigational Agents
  • Technology
    • Immunotherapy
    • STING Pathway
    • APRIL Pathway
    • Scientific Publications
    • Intellectual Property
  • Partnerships
  • Media
    • Press Releases
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Analyst Coverage
    • Stock Information
    • FAQs
  • Careers
  • Contact
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Headquarters
    • Community Affairs
  • Pipeline
    • Clinical Trials
    • Access to Our Investigational Agents
  • Technology
    • Immunotherapy
    • STING Pathway
    • APRIL Pathway
    • Scientific Publications
    • Intellectual Property
  • Partnerships
  • Media
    • Press Releases
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Analyst Coverage
    • Stock Information
    • FAQs
  • Careers
  • Contact
  • Privacy Policy
  • Terms and Conditions of Use
Logo© 2019 Aduro BiotechAll rights reserved
  • Privacy Policy
  • Terms and Conditions of Use
Website Design: Hane Chow, Inc.
TwitterLinkedIn